Healthcare -
Medical - Instruments & Supplies - NASDAQ - US
$ 2.51
-2.4 %
$ 87.2 M
Market Cap
-3.34
P/E
1. INTRINSIC VALUE
Balance Sheet
Microbot Medical Inc.
| Current Assets | 5.82 M |
| Cash & Short-Term Investments | 5.47 M |
| Receivables | 300 K |
| Other Current Assets | 49 K |
| Non-Current Assets | 212 K |
| Long-Term Investments | 0 |
| PP&E | 212 K |
| Other Non-Current Assets | 0 |
| Current Liabilities | 2.46 M |
| Accounts Payable | 165 K |
| Short-Term Debt | 0 |
| Other Current Liabilities | 2.3 M |
| Non-Current Liabilities | 41 K |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 41 K |
EFFICIENCY
Earnings Waterfall
Microbot Medical Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 11.6 M |
| Operating Income | 0 |
| Other Expenses | 11.4 M |
| Net Income | -11.4 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Microbot Medical Inc.
| Net Income | -11.4 M |
| Depreciation & Amortization | 91 K |
| Capital Expenditures | -25 K |
| Stock-Based Compensation | 1.35 M |
| Change in Working Capital | 942 K |
| Others | 1.18 M |
| Free Cash Flow | -8.85 M |
Wall Street Analysts Price Targets
Microbot Medical Inc.
MBOT has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
MBOT does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Microbot Medical Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Microbot Medical® Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers
The addition of a seasoned VP of Marketing compliments the recent hiring of the Company's VP of Sales to establish its commercialization readiness infrastructure
globenewswire.com
- 3 weeks ago
Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System
Successful robotic navigation was achieved in every case and met the primary endpoint of the study LIBERTY ® showed a 92% reduction in radiation exposure with no adverse events reported HINGHAM, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, presented for the first time the data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology (SIR) annual meeting.
globenewswire.com
- 1 month ago
REMINDER: Microbot Medical Announces Data from the Company's ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting
Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter
globenewswire.com
- 1 month ago
Microbot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY® Endovascular Robotic System
Mr. Paul Mullen Most Recently Served as the Director of Sales at Inari Medical which was Acquired by Stryker Corporation Earlier This Year
globenewswire.com
- 2 months ago
Robotic Telesurgery Data from Collaboration with Corewell Health™ Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting
BRAINTREE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced its collaboration with Corewell Health™ has reached another meaningful milestone.
globenewswire.com
- 2 months ago
Microbot Medical Closes $13 Million Registered Direct Offering
BRAINTREE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 6,103,289 shares of the Company's common stock at a purchase price of $2.13 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series I preferred investment options. The short-term series I preferred investment options to purchase up to 12,206,578 shares of common stock have an exercise price of $2.13 per share and will be exercisable for a period of two years beginning on the later of (i) the effective date of the increase of the Company's authorized shares of common stock following stockholder approval and (ii) the effective date of stockholder approval of the issuance of the series I preferred investment options and the shares issuable upon exercise thereof.
globenewswire.com
- 3 months ago
Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
BRAINTREE, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 6,103,289 shares of the Company's common stock at a purchase price of $2.13 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered short-term series I preferred investment options. The short-term series I preferred investment options to purchase up to 12,206,578 shares of common stock have an exercise price of $2.13 per share and will be exercisable for a period of two years beginning on the later of (i) the effective date of the increase of the Company's authorized shares of common stock following stockholder approval and (ii) the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about February 11, 2025, subject to the satisfaction of customary closing conditions.
globenewswire.com
- 3 months ago
Microbot Medical Closes $8.6 Million Registered Direct Offering
BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 3,788,550 shares of the Company's common stock at a purchase price of $2.27 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series H preferred investment options. The short-term series H preferred investment options to purchase up to 7,577,100 shares of common stock have an exercise price of $2.10 per share and are immediately exercisable following issuance for a period of two years thereafter.
globenewswire.com
- 4 months ago
Microbot Medical Raises a Total of Approximately $11.8 Million in Gross Proceeds from Registered Direct Offering and Previously Announced ATM Facility
HINGHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 4,000,001 shares of the Company's common stock at a purchase price of $1.75 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued unregistered short-term series G preferred investment options. The short-term series G preferred investment options to purchase up to 8,000,002 shares of common stock have an exercise price of $1.75 per share and are immediately exercisable following issuance for a period of two years thereafter.
globenewswire.com
- 4 months ago
Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY®
Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025 Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025
globenewswire.com
- 4 months ago
MBOT Stock Gains Following FDA Submission of the LIBERTY System
Microbot Medical announces the submission of its LIBERTY System for FDA marketing clearance.
zacks.com
- 5 months ago
Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access
Livestream Interview Can be Viewed Today at 10:50am ET at Benzinga All Access Live
globenewswire.com
- 5 months ago
8. Profile
Summary
Microbot Medical Inc. MBOT
COUNTRY
US
INDUSTRY
Medical - Instruments & Supplies
MARKET CAP
$ 87.2 M
Dividend Yield
0.00%
Description
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Contact
25 Recreation Park Drive, Hingham, MA, 02043
https://www.microbotmedical.com
IPO
Date
March 25, 1992
Employees
20
Officers
Ms. Rachel Vaknin
Chief Financial Officer
Dr. Simon Sharon MBA, MSc
Chief Technology Officer & GM of Microbot Israel
Ms. Michal Ahuvia
Director of Operations
Naama Moav
Vice President of Human Resources
Mr. Harel Gadot
Co-Founder, President, Chief Executive Officer & Chairman
Mr. Paul Mullen
Vice President of Sales
Dr. Juan Diaz-Cartelle
Chief Medical Officer